当前位置: X-MOL首页SCI期刊查询及投稿分析系统 › Expert Opinion on Orphan Drugs杂志
Expert Opinion on Orphan Drugs
基本信息
期刊名称 Expert Opinion on Orphan Drugs
EXPERT OPIN ORPHAN D
期刊ISSN 2167-8707
期刊官方网站 https://www.tandfonline.com/journals/ieod20
是否OA No
出版商 Taylor and Francis Ltd.
出版周期
文章处理费 登录后查看
始发年份
年文章数 3
影响因子 0.8(2023)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学4区 PHARMACOLOGY & PHARMACY 药学4区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 2.3 0.199 0.294
Pharmacology, Toxicology and Pharmaceutics
Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
14/43 68%
Medicine
Health Policy
183/310 41%
Medicine
Pharmacology (medical)
173/272 36%
补充信息
自引率 5.00%
H-index 13
SCI收录状况 Science Citation Index Expanded
官方审稿时间 登录后查看
网友分享审稿时间 数据统计中,敬请期待。
接受率 登录后查看
PubMed Central (PMC) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2167-8707%5BISSN%5D
投稿指南
期刊投稿网址 https://mc.manuscriptcentral.com/eood
收稿范围
Expert Opinion on Orphan Drugs [e-ISSN 2167-8707] is an international journal publishing rigorously peer-reviewed review articles and original papers on rare diseases and orphan drugs. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

Expert Opinion on Orphan Drugs aims to draw a spotlight on diseases that do not have a high prevalence but have a huge impact on patients and their clinicians, through valuable and high-quality expert insights. In a field which is ever-growing and changing, Expert Opinion on Orphan Drugs is committed to acting as a reliable beacon of guidance and support for researchers, clinicians, patients and advocacy groups in order to optimise research, development, management and quality of life of rare disease patients.

Articles focus on the following key areas:

    Diagnostics, pharmacogenomics and screening;
    Public health and epidemiology;
    Drug development;
    Lead generation and discovery;
    Early or late phase clinical trials;
    Regulatory issues;
    Post-marketing safety and treatment outcomes.

The journal also welcomes solicited and unsolicited papers including Drug Evaluations, specifically reviewing the pharmacological properties, clinical potential/clinical efficacy, safety and, if applicable, HE/OR data on a particular orphan drug, as well as Original Research papers and Editorials.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.

 For any pre-submission enquiries, please contact the Commissioning Editor.

Please note, from 2023 the Print ISSN is not in active use as this journal is no longer published in print.
收录体裁
投稿指南 https://www.tandfonline.com/action/authorSubmission?show=instructions&journalCode=ieod20
投稿模板
参考文献格式
编辑信息

Editor in Chief:

M. Ian Phillips, Director of the Center for Rare Disease Therapies, Keck Graduate Institute


Editorial Board:

Sabina Antoniu, Pulmonary Disease Division, University of Medicine and Pharmacy, Romania

Martin Braddock, Global Medicines Development, AstraZeneca R&D, UK

Maria Luisa Brandi, Unit of Bone and Mineral Metabolism, University of Florence, Italy

Roberto Giugliani, Department of Genetics, Federal University of Rio Grande do Sul, Brazil

Stephen Groft, Director, Office of Rare Diseases, National Institutes of Health, USA

Aaron S. Kesselheim, Harvard Medical School and Brigham and Women's Hospital, USA

Stephen Kingsmore, Center for Pediatric Genomic Medicine, Children's Mercy Hospitals and Clinics, USA

Alex MacKenzie, Pediatrics, CHEO, University of Ottawa, Canada

Maria Mavris, EURORDIS - European Organisation for Rare Diseases, France

Khue Nguyen, University of California, San Diego, USA 

Daniel O'Connor, Medicines and Healthcare Products Regulatory Agency, UK

Manuel Posada, Director, Research Institute for Rare Diseases, Instituto de Salud Carlos III, Spain

Peter L. Saltonstall, President and CEO, National Organization for Rare Disorders (NORD), USA

Michael Shy, Division of Neuromuscular Medicine, University of Iowa, USA

Ali Taher, Division of Hematology/Oncology, American University of Beirut Medical Centre, Lebanon

Eleftherios Tsiridis, Academic Department of Trauma and Orthopaedics, University of Leeds, UK


我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug